Abstract
大规模临床试验显示，新颖口服降糖药钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂能够改善糖尿病和非糖尿病患者心血管预后。SGLT2抑制剂减低心脏负荷、改善心脏代谢和生物能量利用，抑制心肌Na+/H+交换，减少坏死和心肌纤维化，减低炎症因子产生及心外膜脂肪组织含量。然而，急性心肌梗死时，SGLT2抑制剂的作用如何至今尚不清楚。本文就心肌梗死动物实验和临床研究中，SGLT2抑制剂对左心室重构和功能、心律失常和急性肾损伤的作用作一综述。.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
